Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma

Author： Wang M.   Giralt S.   Delasalle K.   Handy B.   Alexanian R.  

Publisher： Maney Publishing

ISSN： 1024-5332

Source： Hematology, Vol.12, Iss.3, 2007-06, pp. : 235-239

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rapid control of previously untreated multiple myeloma with bortezomib–lenalidomide–dexamethasone (BLD)

By Wang M.   Delasalle K.   Giralt S.   Alexanian R.  

Hematology, Vol. 15, Iss. 2, 2010-04 ,pp. : 70-73

Maney Publishing

Access to resources Recommend Favorite

Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety

By Lee Sung   Suh Cheolwon   Kim Bong-Seog   Chung Jooseop   Joo Young-Don   Ryoo Hun-Mo   Do Young   Jin Jong-Youl   Kang Hye   Lee Gyeong-Won   Lee Moon   Shim Hyeok   Kim Kihyun   Yoon Sung-Soo   Bang Soo   Kim Ho   Lee Je-Jung   Park Jinny   Lee Dong   Lee Jae-Hoon  

Annals of Hematology, Vol. 89, Iss. 9, 2010-09 ,pp. : 905-912

Springer Publishing Company

Access to resources Recommend Favorite

A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma

By Chim C.   Lie A.   Chan E.   Leung Y.   Cheung S.   Chan S.   Liang Raymond   Kwong Y.  

Annals of Hematology, Vol. 89, Iss. 10, 2010-10 ,pp. : 1019-1027

Springer Publishing Company

Access to resources Recommend Favorite

Long-term results of thalidomide and dexamethasone (thal–dex) as therapy of first relapse in multiple myeloma

By Zamagni Elena   Petrucci Alessandro   Tosi Patrizia   Tacchetti Paola   Perrone Giulia   Brioli Annamaria   Pantani Lucia   Zannetti Beatrice   Terragna Carolina   Baccarani Michele   Cavo Michele  

Annals of Hematology, Vol. 91, Iss. 3, 2012-03 ,pp. : 419-426

Springer Publishing Company

Access to resources Recommend Favorite

Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma

By Kiyota Miki  

International Journal of Hematology, Vol. 95, Iss. 5, 2012-05 ,pp. : 516-526

Springer Publishing Company

Access to resources Recommend Favorite